Hewang Pharmaceutical (00013) rose nearly 7% in the afternoon. As of press release, it had risen 6.13% to HK$28.55, with a turnover of HK$94.6406 million.
The Zhitong Finance App learned that Hewang Pharmaceutical (00013) rose nearly 7% in the afternoon. As of press release, it had risen 6.13% to HK$28.55, with a turnover of HK$94.6406 million.
Ping An Securities pointed out that sales of the company's core products have maintained rapid growth. Fruquintinib was listed in the US in November 2023. It is the first innovative targeted therapy approved for the treatment of metastatic colorectal cancer in the US in more than 10 years. After only two months of launch, sales in the US market have reached 15.1 million US dollars, and the volume is rapid.
In addition, many of the company's major products are expected to be approved or declared for NDA in '24, which is expected to continuously catalyze an increase in the company's value. The bank said that considering that the indications for the company's listed products are still expanding, and that the company is also developing a rich pipeline, pipeline valuation is expected to further improve and maintain the “recommended” rating.